- NCIt
- C39750
Loading cancer entity…
Loading cancer entity…
Clinical trials
303 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (64)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00102648 | Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT01149850 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2024 |
| clinicaltrials |
| NCT03250299 | Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 26 | Basilea PharmaceuticaINDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06418113 | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma(GLINERA) | recruiting | Phase 1 | 12 | Hospital San Carlos, MadridOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05318612 | Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)(EMITT) | active not recruiting | Phase 3 | 238 | Radboud University Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | completed | Phase 1 | 8 | Istari Oncology, Inc.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT02133183 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2024 | clinicaltrials |
| NCT02052648 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | completed | Phase 1 / Phase 2 | 160 | NewLink Genetics CorporationINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06327451 | Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma | recruiting | Phase 2 | 50 | Tianjin Medical University General HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06283927 | The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)(RECSUR) | recruiting | — | 464 | Jasper GerritsenOTHER | 5 | Feb 28, 2024 | clinicaltrials |
| NCT06118723 | The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)(SUPRAMAX) | recruiting | — | 784 | Jasper GerritsenOTHER | 5 | Feb 22, 2024 | clinicaltrials |
| NCT06273176 | The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma(RECMAP) | recruiting | — | 225 | Erasmus Medical CenterOTHER | 5 | Feb 22, 2024 | clinicaltrials |
| NCT01922076 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Jan 31, 2024 | clinicaltrials |
| NCT06160596 | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis(ROSALIND) | recruiting | — | 1,020 | Cure 51OTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06146725 | The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)(RESBIOP) | recruiting | — | 564 | Jasper GerritsenOTHER | 5 | Nov 27, 2023 | clinicaltrials |
| NCT06146738 | The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)(PALSUR) | recruiting | — | 1,015 | Jasper GerritsenOTHER | 5 | Nov 27, 2023 | clinicaltrials |
| NCT02168270 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | terminated | Phase 1 | 4 | University of NebraskaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03027388 | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01957956 | Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | completed | Early Phase 1 | 21 | Mayo ClinicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02658981 | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | completed | Phase 1 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02386826 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 1 | 65 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03360708 | Vaccine Therapy in Treating Patients With Recurrent Glioblastoma | completed | Early Phase 1 | 20 | Mayo ClinicOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02661282 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | completed | Phase 1 / Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02366728 | DC Migration Study for Newly-Diagnosed GBM(ELEVATE) | completed | Phase 2 | 64 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT00662506 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2023 | clinicaltrials |
| NCT01721577 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas(AXL1717) | terminated | Phase 1 / Phase 2 | 10 | Rush University Medical CenterOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification(Intellance1) | completed | Phase 3 | 691 | AbbVieINDUSTRY | 28 | May 11, 2023 | clinicaltrials |
| NCT03860376 | Ex Vivo Drug Sensitivity Testing and Mutation Profiling | completed | — | 25 | Florida International UniversityOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05842746 | Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma | not yet recruiting | Phase 2 | 74 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT04091503 | Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | completed | Phase 1 | 30 | Center Trials & Treatment EuropeNETWORK | 3 | Apr 25, 2023 | clinicaltrials |
| NCT05326334 | THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)(THERABIOME-GBM) | recruiting | — | 20 | Ottawa Hospital Research InstituteOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05100641 | AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM | not yet recruiting | Phase 3 | 672 | Aivita Biomedical, Inc.INDUSTRY | 0 | Apr 10, 2023 | clinicaltrials |
| NCT02664363 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma(ExCeL) | terminated | Phase 1 | 3 | Daniel LandiOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT00100802 | Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05694416 | Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma | unknown | Phase 2 | 60 | Zhongnan HospitalOTHER | 0 | Jan 23, 2023 | clinicaltrials |
| NCT04657315 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients(MSC11FCD-GBM) | completed | Phase 1 / Phase 2 | 10 | CHA UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02311920 | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | completed | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT01730950 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 182 | Radiation Therapy Oncology GroupNETWORK | 1 | Dec 29, 2022 | clinicaltrials |
| NCT01822275 | Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme(GCC 1224) | terminated | Phase 2 | 24 | University of Maryland, BaltimoreOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05017610 | Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma | withdrawn | Early Phase 1 | 0 | Emory UniversityOTHER | 0 | Dec 2, 2022 | clinicaltrials |
| NCT03020017 | NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery | completed | Early Phase 1 | 8 | Northwestern UniversityOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM(CYNK001GBM01) | terminated | Phase 1 | 3 | Celularity IncorporatedINDUSTRY | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04926168 | 6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM) | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 10, 2022 | clinicaltrials |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01062425 | Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 2 | 261 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01609790 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 2 | Jul 21, 2022 | clinicaltrials |
| NCT03367715 | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | completed | Phase 2 | 10 | NYU Langone HealthOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | terminated | Phase 1 / Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT03641326 | Sunitinib in Sarcomas of the Central Nervous System | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 17, 2024source: clinicaltrials